Company / Operating Cash Flow
Perspective Therapeutics, Inc. Operating Cash Flow History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$7.7M
FY2022
5-year range
-$7.7M / -$3.9M
FY2018-FY2022
Trend
-52.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$6M to -$8M over the past 2 years.
Based on SEC 10-K filings.
-$8M in FY2022.
Declined from -$6M to -$8M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating cash flow decreased 52.7% year-over-year.
- Peak operating cash flow was recorded in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$7.7M | -52.7% |
| FY2021 | -$5.0M | +11.6% |
| FY2020 | -$5.7M | +0.0% |
| FY2019 | -$5.7M | -47.1% |
| FY2018 | -$3.9M | -10.3% |
| FY2017 | -$3.5M | -9.1% |
| FY2016 | -$3.2M | -5.6% |
| FY2015 | -$3.1M | +0.0% |
| FY2014 | -$3.1M | -24.9% |
| FY2013 | -$2.4M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026